The extra domain a of fibronectin increases VEGF-C expression in colorectal carcinoma involving the PI3K/AKT signaling pathway

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Xiang, Lisha ^a   Xie, Ganfeng ^a   Ou, Juanjuan ^a   Wei, Xing ^a   Pan, Feng ^a   Liang, Houjie ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EXTRA DOMAIN A CONTAINING FIBRONECTIN; FIBRONECTIN; LENTIVIRUS VECTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; VASCULOTROPIN C; 2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; ENZYME INHIBITOR; EXTRA DOMAIN A FIBRONECTIN, HUMAN; MORPHOLINE DERIVATIVE; SMALL INTERFERING RNA; VEGFC PROTEIN, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER STAGING; CANCER TISSUE; CARCINOGENICITY; COLON MUCOSA; COLORECTAL CARCINOMA; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN SECRETION; RECTUM MUCOSA; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING; AGED; ANIMAL; BIOSYNTHESIS; CARCINOMA; CELL CULTURE; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; TUMOR CELL LINE;

AGED; ANIMALS; CARCINOMA; CELL LINE, TUMOR; CELLS, CULTURED; CHROMONES; COLORECTAL NEOPLASMS; ENZYME INHIBITORS; FEMALE; FIBRONECTINS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MALE; MICE; MIDDLE AGED; MORPHOLINES; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR C; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859508728     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035378     Document Type: Article

References (36)

1. Sundlisaeter E, Dicko A, Sakariassen PØ, Sondenaa K, Enger PØ, et al. (2007) Lymphangiogenesis in colorectal cancer--prognostic and therapeutic aspects. Int J Cancer 121: 1401-1409.
2. Saad RS, Lindner JL, Liu Y, Silverman JF, (2009) Lymphatic vessel density as prognostic marker in esophageal adenocarcinoma. Am J Clin Pathol 131: 92-98.
3. Liu HT, Ma R, Yang QF, Du G, Zhang CJ, (2009) Lymphangiogenic characteristics of triple negativity in node-negative breast cancer. Int J Surg Pathol 17: 426-431.
4. Clasper S, Royston D, Baban D, Cao Y, Ewers S, et al. (2008) A novel gene expression profile in lymphatics associated with tumor growth and nodal metastasis. Cancer Res 68: 7293-7303.
5. Barresi V, Reggiani-Bonetti L, Di Gregorio C, De Leon MP, Barresi G, (2011) Lymphatic vessel density and its prognostic value in stage I colorectal carcinoma. J Clin Pathol 64: 6-12.
6. Duff SE, Li C, Renehan A, O'Dwyer ST, Kumar S, (2003) Immunodetection and molecular forms of plasma vascular endothelial growth factor-C. Int J Oncol 22: 339-343.
7. Kim JG, Chae YS, Sohn SK, Cho YY, Moon JH, et al. (2008) Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res 14: 62-66.
8. Parr C, Jiang WG, (2003) Quantitative analysis of lymphangiogenic markers in human colorectal cancer. Int J Oncol 23: 533-539.
9. Royston D, Jackson DG, (2009) Mechanisms of lymphatic metastasis in human colorectal adenocarcinoma. J Pathol 217: 608-619.
10. Krishnan J, Kirkin V, Steffen A, Hegen M, Weih D, et al. (2003) Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res 63: 713-722.
11. Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Ylä-Herttuala S, et al. (2001) Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 61: 1786-1790.
12. Beasley NJ, Prevo R, Banerji S, Leek RD, Moore J, et al. (2002) Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res 62: 1315-1320.
13. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, et al. (2001) Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 20: 672-682.
14. Achen MG, McColl BK, Stacker SA, (2005) Focus on lymphangiogenesis in tumor metastasis. Cancer Cell 7: 121-127.
15. Pepper MS, (2001) Lymphangiogenesis and tumor metastasis: myth or reality. Clin Cancer Res 7 pp. 462-468.
16. Villa A, Trachsel E, Kaspar M, Schliemann C, Sommavilla R, et al. (2008) A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 122: 2405-2413.
17. Romberger DJ, (1997) Fibronectin. Int J Biochem Cell Biol 29: 939-943.
18. McFadden JP, Baker BS, Powles AV, Fry L, (2010) Psoriasis and extra domain A fibronectin loops. Br J Dermatol 163: 5-11.
19. van der Straaten HM, Canninga-van Dijk MR, Verdonck LF, Castigliego D, Borst HP, et al. (2004) Extra-domain-A fibronectin: a new marker of fibrosis in cutaneous graft-versus-host disease. J Invest Dermatol 123: 1057-1062.
20. Ou JJ, Wu F, Liang HJ, (2010) Colorectal tumor derived fibronectin alternatively spliced EDA domain exserts lymphangiogenic effect on human lymphatic endothelial cells. Cancer Biology & Therapy 9: 186-191.
21. Tang Y, Zhang D, Fallavollita L, Brodt P, (2003) Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor. Cancer Res 63: 1166-1171.
22. Oliver G, Detmar M, (2002) The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. Genes Dev 16: 773-783.
23. Caunt M, Mak J, Liang WC, Stawicki S, Pan Q, et al. (2008) Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 13: 331-342.
24. Bahram F, Claesson-Welsh L, (2010) VEGF-mediated signal transduction in lymphatic endothelial cells. Pathophysiology 17: 253-261.
25. Girling JE, Rogers PA, (2009) Regulation of endometrial vascular remodelling: role of the vascular endothelial growth factor family and the angiopoietin-TIE signalling system. Reproduction 138: 883-893.
26. Saintigny P, Kambouchner M, Ly M, Gomes N, Sainte-Catherine O, et al. (2007) Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: concurrent expression in cancer cells from primary tumour and metastatic lymph node. Lung Cancer 58: 205-213.
27. Chang L, Kaipainen A, Folkman J, (2002) Lymphangiogenesis new mechanisms. Ann N Y Acad Sci 979: 111-119.
28. Su JL, Chen PS, Chien MH, Chen PB, Chen YH, et al. (2008) Further evidence for expression and function of the VEGF-C/VEGFR-3 axis in cancer cells. Cancer Cell 13: 557-560.
29. Tammela T, Alitalo K, (2010) Lymphangiogenesis: Molecular Mechanisms and Future Promise. Cell 140: 460-476.
30. Enholm B, Paavonen K, Ristimäki A, Kumar V, Gunji Y, et al. (1997) Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 14: 2475-2483.
31. Avraamides CJ, Garmy-Susini B, Varner JA, (2008) Integrins in angiogenesis and lymphangiogenesis. Nature Reviews Cancer 8: 604-617.
32. Skinner HD, Zheng JZ, Fang J, Agani F, Jiang BH, (2004) Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J Biol Chem 279: 45643-45651.
33. Saji M, Ringel MD, (2010) The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol 321: 20-28.
34. West KA, Castillo SS, Dennis PA, (2002) Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 5: 234-248.
35. Goc A, Al-Husein B, Kochuparambil ST, Liu J, Heston WW, et al. (2011) PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer. International Journal of Oncology 38: 267-277.
36. Duan GJ, Yan XC, Bian XW, Li J, Chen X, (2004) [The significance of beta-catenin and matrix metalloproteinase-7 expression in colorectal adenoma and carcinoma]. Zhonghua bing li xue za zhi Chinese journal of pathology 33: 518-522.